about
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.Olanzapine. Pharmacokinetic and pharmacodynamic profile.Fluoxetine: a review of receptor and functional effects and their clinical implications.Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report.Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement.Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis.Blood pressure changes during short-term fluoxetine treatment.Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.Hematologic reference ranges in a population of patients with schizophrenia.Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial.Fluoxetine in medically stable, depressed geriatric patients: effects on weight.Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials.Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Fluoxetine: no association with suicidality in obsessive-compulsive disorderOlanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trialOlanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trialFluoxetine efficacy in menopausal women with and without estrogen replacementOlanzapine plasma concentrations and clinical response in acutely ill schizophrenic patientsUse of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placeboAll-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisSystematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditionsDesign and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings
P50
Q31136498-D8FC6EC5-D720-4C41-93C9-DC1A92DC93DEQ33747095-9C33A3B8-C247-486A-9273-7B6A36CA6359Q35228372-3890D4AC-66B0-466C-8175-1ABC5A62C34BQ36629252-B058BEE1-4FD3-49D9-8B2A-4D3AC280C928Q36886387-03AAB739-CAF7-4A72-B5D9-A71E9735AD50Q37776770-73A37E64-BA51-47D7-8563-8FC4D28B739DQ37783373-6839BF9D-9F81-4861-B180-F6E786851162Q40277097-7A31D630-FB6E-4833-9E93-3ED63BDB2101Q42536275-3E62F2BB-3AFC-4ECB-8AB7-3925BD93169BQ42537403-352466B7-3040-4517-8D1B-C01A8886D0CDQ42606458-029D5A4F-0F34-4643-843F-1CAB1D8BD44CQ43837440-AD4A5077-FF4F-4654-BB68-BD4A0C80D16EQ43942941-D6D6A0B5-8D60-44F8-84F5-03C151D673C2Q44018213-E7B07080-19B0-44C9-9DD1-4DA42CD723D7Q44512849-351000C1-ABC5-475A-B90F-3FD33C682F2FQ44546079-8EFA2A23-0580-485A-B2F0-681F03DF03B9Q44812247-D36060CD-2633-4501-B5B2-957F9709B320Q46468828-8CA8716F-4B08-47BD-AC66-83040579D61FQ46648616-89094C6A-BA36-4BB4-8276-20177404F6BAQ46686693-AAC1A2F8-0920-4DF3-AB28-FA38B423A4B8Q46896031-481063F8-FED0-4301-B1C6-E3FDF8A692FBQ46901038-420C8A41-BA9C-4C58-8C32-BB891E01455BQ47301791-B83E14A9-AC7F-4B70-9565-5A99894E71E9Q47427837-54A96C91-2C23-469D-8919-E7449EA2EAACQ48708119-1DE44B7B-A7F0-48BD-9951-ADF2C936595EQ51097389-D797E6FB-C5F9-49D1-A387-DC5AAA8635F1Q51981823-99F1DC52-AA3B-46F6-80A6-A38C4CE6188BQ53360074-5BD1286C-02E7-4DA8-A05C-F0245F4E851CQ53586486-0891995A-69E9-49F3-A64C-0F663A09C664Q53589905-6368099A-E642-45F1-B7C8-AD98233EF096Q68070975-C6315951-A66B-4FEF-8B95-8F4EB86D45A3Q71570144-1ABAD2F3-F1D4-4663-B6B4-765E4FCBAC8CQ71816819-366A67DA-B46B-431E-A993-FC0ED7F55EB2Q73061974-4D2C6A34-982B-407C-87EA-63204D240B23Q73964547-4E1E8EE8-DFD8-4FEC-B399-9495EE8C3A53Q74468692-8B0CBA81-B6E1-49F0-8454-BF2D34058613Q80336937-EA861123-9DC1-4805-A6DD-7DE1FA083EA8Q84013362-E9841D77-8576-4421-AD9D-9F3C990289B5Q87070578-C28167FA-32BD-4CF6-9B03-340382B78DFB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Charles M. Beasley
@ast
Charles M. Beasley
@en
Charles M. Beasley
@es
Charles M. Beasley
@nl
Charles M. Beasley
@sl
type
label
Charles M. Beasley
@ast
Charles M. Beasley
@en
Charles M. Beasley
@es
Charles M. Beasley
@nl
Charles M. Beasley
@sl
prefLabel
Charles M. Beasley
@ast
Charles M. Beasley
@en
Charles M. Beasley
@es
Charles M. Beasley
@nl
Charles M. Beasley
@sl
P106
P1153
7102979747
P21
P31
P496
0000-0001-8743-7691